Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04832061 · ClinicalTrials.gov registry record

Respiratory Supports and COVID-19 Mortality

A clinical trial of COVID-19, sponsored by Yale University.

Completed
Registry status
2,300
Enrollment target
1
Study location

NCT04832061: Completed study of COVID-19, sponsored by Yale University.

NCT04832061 is a study of COVID-19 that has completed, run by Yale University. The registered enrollment target is 2,300 participants, below the 38,457-participant average among 298 other COVID-19 trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04832061, a study of COVID-19, has completed, sponsored by Yale University.

COMPLETED
Registry status
2,300 participants
Enrollment target
1
Study location

Study Summary

Critically ill COVID-19 patients have a relatively high mortality rate (\~30%). Most critically ill COVID-19 patients require respiratory supports. The respiratory supports used in this patient population included conventional oxygen therapy (COT) via nasal cannula or face mask, non-invasive ventilation (NIV), and invasive mechanical ventilation (IMV). NIV has three different methods, including high-flow nasal cannula (HFNC), bilevel positive airway pressure (BiPAP), and continuous positive airway pressure (CPAP). There are outstanding questions that remain to be answered. One is which NIV is more effective; the other is if the use of IMV leads to increased mortality. Another relevant question is if ventilator settings (such as tidal volume, drive pressure, and positive end-expiratory pressure) are associated with different mechanical ventilated patients' outcomes. To answer these questions, a retrospective cohort study based on all patients who had been treated in the ICUs in Yale New Haven Health System throughout the first pandemic year was designed.

Primary Outcome

the number of all-cause death during hospitalization divided by the number of patients who were discharged from hospital or remained hospitalized but alive on the last day of data extraction

Conditions Studied

Interventions

  • OTHER Respiratory supports

Study Locations (1)

Connecticut

  • Yale University School of Medicine - New Haven

Trial Details

FieldValue
Enrollment Target 2,300 participants
Start Date 2021-04-01
Est. Completion 2021-04-20
Yale University

1,492 total trials

What the finished NCT04832061 record still lists

NCT04832061 is an observational study that tracks outcomes without assigning an intervention. Its 2,300 participants enrollment target places it among the larger protocols in the corpus, below the 38,457-participant average among 298 other COVID-19 trials with a reported enrollment target (94% lower).

The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Respiratory supports is the first listed.

NCT04832061 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT04832061 about?

NCT04832061 is a clinical study titled "Respiratory Supports and COVID-19 Mortality". Critically ill COVID-19 patients have a relatively high mortality rate (\~30%). Most critically ill COVID-19 patients require respiratory supports. The respiratory supports used in this patient population included conventional oxygen therapy (COT) via nasal cannula or face mask, non-invasive ventila...

What is the current status of trial NCT04832061?

This trial is currently completed. The enrollment target is 2,300 participants. The study started on 2021-04-01. Estimated completion is 2021-04-20.

What conditions does trial NCT04832061 study?

This clinical trial studies the following conditions: COVID-19.

What interventions are being tested in trial NCT04832061?

The interventions under investigation include: Respiratory supports (OTHER).

Who is sponsoring clinical trial NCT04832061?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04832061 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04832061's enrollment target sits among peer trials

2,300 41st of 298 higher than 258 of 298 other COVID-19 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04124120 · 2,300 participants · NA

    Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

  • NCT05237258 · 2,300 participants · NA

    Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

  • NCT05732623 · 2,300 participants

    Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

  • NCT05759988 · 2,300 participants · NA

    Cervical Ripening as an Outpatient Method Using the Foley (COMFORT)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04832061, the US trial registry maintained by the National Library of Medicine. NCT04832061 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.